Mission
To improve drug development decisions and treatment outcomes through a better understanding of biological differences between patients.
About EndoVia
Individual biology. Collective expertise.
Patients are biologically different. Medicines should be developed with that in mind.
Mission and vision
Vision
To build advanced data models that integrate biological data with machine learning to advance precision oncology.
Our origins
EndoVia Therapeutics is a spin-out of the University of Maribor, built on years of research at the Institute of Biomedical Sciences in pharmacology, cell biology and cannabinoid science. We hold an exclusive license to our core IP and bring laboratory biology and computational modeling together in one in-house team, so experiments and models are designed side by side.
Founded 2025 · University of Maribor spin-out
Team
Jan Rožanc, PhD
Co-founder & CEO
LinkedIn ↗
Uroš Maver, PhD
Co-founder & CSO
LinkedIn ↗
Marko Milojević, PhD
Co-founder
LinkedIn ↗
Klemen Zupančič, PhD
Head of Business Development
LinkedIn ↗
Lidija Gradišnik, PhD
Head of Lab Operations
Sébastien De Landtsheer, PhD
Head of Computational Biology
LinkedIn ↗
Boris Gole, PhD
Senior Scientist
LinkedIn ↗Špela Bukovec
Researcher
Metka Vrečko
Researcher
Advisors
Prof. Thomas Sauter, PhD
Professor of Systems Biology, University of Luxembourg
LinkedIn ↗
Luka Dobovišek, MD
Medical oncologist, Institute of Oncology Ljubljana
LinkedIn ↗
Prof. Tamara Lah Turnšek, PhD
Cancer biology, National Institute of Biology (former director)
LinkedIn ↗Partners and funders
Careers
We are growing our laboratory and computational team. Current openings: Laboratory Scientist (Maribor). No matching role? Send a short note and CV to info@endovia.eu.
Contact us about careers